Henry Fernandez Steps Down from Royalty Pharma's Board of Directors
NEW YORK, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Royalty Pharma Board of Directors in July 2020 ...
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025.
Theravance Sales Jump 83 Percent
Theravance Biopharma ( NASDAQ:TBPH ) , a biopharmaceutical company focused on respiratory medicines and rare disease therapeutics, reported its Q2 2025 results on August 12, 2025. The company's revenue ( GAAP ) grew to $26.2 million, slightly ahead of analyst estimates at $25.93 million.
Here's How Much $1000 Invested In Royalty Pharma 15 Years Ago Would Be Worth Today - Royalty Pharma ( NASDAQ:RPRX )
Royalty Pharma RPRX has outperformed the market over the past 15 years by 36.41% on an annualized basis producing an average annual return of 48.86%. Currently, Royalty Pharma has a market capitalization of $15.45 billion.
Royalty Pharma ( RPRX ) Q2 Receipts Up 20%
Royalty Pharma Plc ( NASDAQ:RPRX ) , a leader in acquiring royalties on biopharmaceutical products, released second quarter results on August 6, 2025. The most notable news: Royalty Receipts-its closest revenue proxy-rose 11% to $672 million but landed just under the $672.99 million analyst ...
Royalty Pharma ( RPRX ) Tops Q2 Earnings and Revenue Estimates
Royalty Pharma (RPRX) delivered earnings and revenue surprises of +3.64% and +5.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Countdown to Royalty Pharma ( RPRX ) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Royalty Pharma (RPRX) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update
Agios Pharmaceuticals today announced financial results and updates for the second quarter ended June 30, 2025.
Royalty Pharma ( RPRX ) Earnings Expected to Grow: Should You Buy?
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Invesco Biotechnology & Genome ETF ( PBE ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Royalty Pharma Declares Third Quarter 2025 Dividend
NEW YORK, July 18, 2025 ( GLOBE NEWSWIRE ) -- The board of directors of Royalty Pharma plc ( Nasdaq: RPRX ) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share.
Royalty Pharma Declares Third Quarter 2025 Dividend - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, July 18, 2025 ( GLOBE NEWSWIRE ) -- The board of directors of Royalty Pharma plc RPRX has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on September 10, 2025, to shareholders of record at the close of ...
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors
NEW YORK, July 17, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced the appointment of Carole Ho and Elizabeth ( Bess ) Weatherman to its Board of Directors, effective immediately. Carole Ho is Chief Medical Officer and Head of Development at Denali Therapeutics, a ...
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors - Royalty Pharma ( NASDAQ:RPRX )
Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90% Underscores Royalty Pharma's commitment to enhanced corporate governance following acquisition of its external manager
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025
NEW YORK, July 16, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will report its second quarter 2025 financial results on Wednesday, August 6, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at ...
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025 - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, July 16, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will report its second quarter 2025 financial results on Wednesday, August 6, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.
Should You Invest in the iShares U.S. Pharmaceuticals ETF ( IHE ) ?
Sector ETF report for ...
Revolution Medicines To Advance Lead Cancer Drug With Funding Worth $2B - Royalty Pharma ( NASDAQ:RPRX ) , Revolution Medicines ( NASDAQ:RVMD )
The deal includes up to $1.25 billion in royalties and $750M in corporate debt for daraxonrasib. Royalty rate on sales over $8 billion drops to zero under 15-year funding agreement. See how Matt Maley is positioning for global volatility, sector rotations, and macro shifts-live this Wednesday, ...
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
NEW YORK, June 24, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced a $2 billion funding arrangement with Revolution Medicines, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and a senior secured loan of up to $750 million.
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion - Royalty Pharma ( NASDAQ:RPRX )
Up to $1.25 billion ( $250 million upfront ) of synthetic royalty funding and up to $750 million in secured debt Innovative partnership enables Revolution Medicines to retain control over pipeline development and global commercialization of daraxonrasib
Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS ( ON ) Inhibitor Portfolio for Patients with RAS-Addicted Cancers - Revolution Medicines ( NASDAQ:RVMD )
Flexible funding provides $2 billion in committed capital comprised of up to $1.25 billion of synthetic royalty and up to $750 million in corporate debt Company moving forward with independent global commercialization strategy to prioritize patient reach and maximize shareholder value
A Look Into Royalty Pharma Inc's Price Over Earnings - Royalty Pharma ( NASDAQ:RPRX )
In the current market session, Royalty Pharma Inc. RPRX stock price is at $34.26, after a 1.72% drop. However, over the past month, the company's stock went up by 7.75%, and in the past year, by 30.95%.
How Is The Market Feeling About Royalty Pharma? - Royalty Pharma ( NASDAQ:RPRX )
Royalty Pharma's RPRX short percent of float has risen 40.0% since its last report. The company recently reported that it has 29.02 million shares sold short, which is 7.0% of all regular shares that are available for trading.
Kailera Therapeutics Appoints Adam Koppel and Christopher Hite to Board of Directors
BOSTON and SAN DIEGO, June 05, 2025 ( GLOBE NEWSWIRE ) -- Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions, today announced the appointments of Adam Koppel ...
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
NEW YORK, June 04, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET.
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, June 04, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET.
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises
Theravance to sell its remaining Trelegy royalty interest to GSK for $225M, with shares jumping 22% on the deal's announcement.
Royalty Pharma Completes the Acquisition of Its External Manager
NEW YORK, May 16, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC ( "RP Management" ) . The acquisition received overwhelming support from Royalty Pharma's shareholders, with ...
Royalty Pharma Completes the Acquisition of Its External Manager - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, May 16, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC ( "RP Management" ) . The acquisition received overwhelming support from Royalty Pharma's shareholders, with 99.9% of ...
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition
NEW YORK, May 12, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that shareholders overwhelmingly approved its previously announced external manager acquisition, with 99.9% voting in favor at Royalty Pharma's 2025 Annual General Meeting and Special Meeting of ...
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition - Royalty Pharma ( NASDAQ:RPRX )
Received overwhelming shareholder approval with 99.9% of votes cast in favor Simplified structure benefits shareholders through strengthened shareholder alignment, enhanced governance, significant cash savings and increased economic return on investments
Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y
TBPH reports weaker-than-expected first-quarter 2025 results. Collaboration revenues from Viatris rise year over year.
Royalty Pharma ( RPRX ) Surpasses Q1 Earnings and Revenue Estimates
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 7.07% and 5.72%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Royalty Pharma Reports First Quarter 2025 Results
NEW YORK, May 08, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts.
Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update - Cytokinetics ( NASDAQ:CYTK )
PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to December 26, 2025 Topline Results from MAPLE-HCM Expected in May Enrollment Completed in ACACIA-HCM; Topline Results Expected in 1H 2026 ~$1.1 Billion in Cash, Cash Equivalents and Investments as of March 31, 2025
Unlocking Q1 Potential of Royalty Pharma ( RPRX ) : Exploring Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Royalty Pharma (RPRX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Warren Buffett Is Set to Step Down as Berkshire Hathaway CEO at the End of 2025: Here's What Will and Won't Change ( and What Already Has )
It's the end of an era for the Oracle of Omaha.
Royalty Pharma ( RPRX ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alerus ( ALRS ) Q1 Earnings and Revenues Top Estimates
Alerus (ALRS) delivered earnings and revenue surprises of 30.23% and 5.42%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Royalty Pharma Declares Second Quarter 2025 Dividend
NEW YORK, April 21, 2025 ( GLOBE NEWSWIRE ) -- The board of directors of Royalty Pharma plc ( Nasdaq: RPRX ) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share.
Royalty Pharma Declares Second Quarter 2025 Dividend - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, April 21, 2025 ( GLOBE NEWSWIRE ) -- The board of directors of Royalty Pharma plc RPRX has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on June 10, 2025, to shareholders of record at the close of ...
Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025
NEW YORK, April 17, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 ...
Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025 - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, April 17, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m.
Is First Trust Health Care AlphaDEX ETF ( FXH ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors
NEW YORK, April 08, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced the appointment of Vlad Coric, M.D. to the company's Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company ...
Should You Invest in the First Trust Health Care AlphaDEX ETF ( FXH ) ?
Sector ETF report for ...
Royalty Pharma Announces Upcoming Investor Day
NEW YORK, March 27, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 a.m. ET. Royalty Pharma senior executives will provide an update on the company's plans to drive ...
Royalty Pharma Announces Upcoming Investor Day - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, March 27, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 a.m.
Why Is Blue Owl Capital Corporation ( OBDC ) Down 3% Since Last Earnings Report?
Blue Owl Capital Corporation (OBDC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
How Do Investors Really Feel About Royalty Pharma? - Royalty Pharma ( NASDAQ:RPRX )
Royalty Pharma's RPRX short percent of float has fallen 10.08% since its last report. The company recently reported that it has 13.75 million shares sold short, which is 3.3% of all regular shares that are available for trading.
